NCT02974257

Thiamine vs. Placebo to Increase Oxygen Consumption After Cardiac Arrest

Terminated Phase 2 Results posted Last updated 10 April 2025

What this trial tests

Phase 2 trial testing Thiamine in Cardiac Arrest in 41 participants. Terminated before completion.

Timeline

1 May 2017

Primary endpoint
7 February 2022

1 August 2022

Quick facts

Lead sponsor	Beth Israel Deaconess Medical Center
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	41
Start date	1 May 2017
Primary completion	7 February 2022
Estimated completion	1 August 2022
Sites	1 location across United States

Drugs / interventions tested

• Thiamine (THIAMINE) — full drug profile →
• placebo

Conditions studied

• Cardiac Arrest — all drugs for Cardiac Arrest →
• Shock — all drugs for Shock →
• Lactic Acidosis — all drugs for Lactic Acidosis →
• Thiamin Deficiency — all drugs for Thiamin Deficiency →

Sponsor

Beth Israel Deaconess Medical Center

Who can join

18 and older, any sex, with Cardiac Arrest or Shock. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Lactate Primary · 2 days

The investigators will evaluate the median lactate level over two days, compared between groups

Group	Value	95% CI
Thiamine	1.9	1.1 – 7.5
Placebo	1.8	1.2 – 5.4

Oxygen Consumption Secondary · 2 days

The investigators will evaluate the mean oxygen consumption over two days, compared between groups

Group	Value	95% CI
Thiamine	3.83	± 0.94
Placebo	3.48	± 1.27

Pyruvate Dehydrogenase Secondary · 2 days

The investigators will evaluate the median pyruvate dehydrogenase levels over two days, compared between groups

Group	Value	95% CI
Thiamine	1.2	0.9 – 1.5
Placebo	1.1	1.0 – 1.3

Sponsor's own description

This study is to evaluate whether thiamine can increase oxygen consumption and lower lactate in patients who initially survive an in-hospital cardiac arrest. Patients who are successfully resuscitated after an in-hospital cardiac arrest and who are on mechanical ventilation in the intensive care unit will be enrolled, and will get either thiamine or placebo. Their oxygen consumption and lactate will be measured at serial time points and compared between groups. The investigators' hypothesis is that thiamine will help restore the body's ability to metabolize oxygen normally (aerobic metabolism), leading to an increase in oxygen consumption and a decrease in lactate.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

1. Clinical targeting of the cerebral oxygen cascade to improve brain oxygenation in patients with hypoxic-ischaemic brain injury after cardiac arrest.
   Hoiland RL, Robba C, Menon DK, Citerio G, et al · · 2023 · cited 36× · PMID 37507572 · DOI 10.1007/s00134-023-07165-x
2. Thiamine for the Treatment of Cardiac Arrest-Induced Neurological Injury: A Randomized, Blinded, Placebo-Controlled Experimental Study.
   Vammen L, Johannsen CM, Baltsen CD, Nørholt C, et al · · 2023 · cited 8× · PMID 36942758 · DOI 10.1161/jaha.122.028558
3. The Impact of Extended-Hours Patient Recruitment on Critical Care Clinical Trial Enrollment.
   Lee JH, Vine J, Meier M, Berkovitz A, et al · · 2025 · PMID 40138529 · DOI 10.1097/cce.0000000000001239
4. Oxygen metabolism after cardiac arrest: Patterns and associations with survival.
   Shea MG, Balaji L, Grossestreuer AV, Issa MS, et al · · 2024 · PMID 38827271 · DOI 10.1016/j.resplu.2024.100667